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Radiotherapy is a frequently used method for treatment of cancer which is regarded as one of the top two diseases 
causing premature death worldwide. However, radiotherapy is known to have many side effects. In this study, we evaluated 
biologically and histologically the possible protective effects of edaravone, the free radical scavenger and neuroprotective 
agent used to treat amyotrophic lateral sclerosis, on lung and small intestine against radiation-induced early side effects of 
15 Gy total body irradiation in single fraction. Thirty-two rats were divided randomly into four equal groups. Groups were 
administered 15 Gy of external ionizing radiation to the whole body after 30 minutes of EDA administration (a dose of 500 
and 50 mg/kg). Rats were sacrified at 72 h of the experiment. Tissues were separated to investigate levels of superoxide 
dismutase (SOD), catalase (CAT), glutathione peroxidase (GSHPX) and malondialdehyde (MDA); and evealuate 
histopathological changings. The protective effect of EDA showed statistically significant in MDA, SOD and GSHPX 
values of lungs except CAT and statistically significant effect was observed in MDA in small intestine. Also, we showed 
statistically significant values with histopathological changings. Pediatric cancer patients who have a longer life expectancy 
are as important as their recovery from their normal life. We are expecting that EDA as a modulator of free radical 
scavenging pathways in many organs can reduce the side effects of radiation damage on lungs and small intestine. 
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Worldwide, cancer is reported to be the primary cause 
of premature death in every country1. According to 
the World Health Organization (WHO), cancer is 
either first or second cause of death in majority of the 
countries. With an estimated 19.3 million new cases, 
cancer causes 10 million deaths across the globe2. 
The global cancer burden by 2040 is estimated to be 
28.4 million cases, 47% rise from 20202. Currently, 
the average childhood cancer burden (<15 years of 
age) is reported to be 140 new cases per million 
children1. In USA alone, approximately, one in 285 
children are diagnosed with cancer each year, and at 
any one time, thousands of children are living with 
cancer3,4.  
Radiation therapy using ionizing radiation is one of 
the treatment approaches for cancer. It is a local 
treatment and has the advantage of being non-invasive 
and potentially organ preserving. It is an important 
therapy in the multimodal treatment for mostly seen 
childhood solid tumours in abdomen like 
neuroblastoma or Wilm’s tumor5,6 and thorax 
metastasis of Ewing sarcoma or Hodgkin lymphoma7. 
Nevertheless, like other treatments, radiation therapy 
causes some side effects especially in the commonly 
used abdominal and thoracic region. The most early 
side effects of thoracic radiation therapy are 
difficulty of swallowing, shortness of breath, breast 
or nipple soreness, cough, fever, fullness of the 
chest, tyhroid dysfunction and radiation fibrosis8-10. 
Radiation fibrosis can engender permanent scarring 
of the lungs from untreated radiation pneumonitis.
High radiation dose can also cause stenosis, occlusion 
or fistula formation and rib fractures resulting 
death11-14. Intestinal epithelium renewal is rapid 
and hence the small intestine is reported to be 
radiosensitive15. The most common side effects of 
radiation therapy to the abdomen are diarrhea, nausea, 
vomiting, constipation, abdominal pain, colitis, 
tenesmus, rectal bleeding, proctalgia, incontinence, 
loss of appetite and weight loss16,17.  
In this context, the necessity to improve outcomes, 
particularly for children with cancer looking at the 
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increased risk, invites attention of researchers on 
treatment methods or side effects18. Some natural 
compounds and herbal extracts have also been found 
effective for radiation injuries19. Since it is not always 
possible to treat early and late effects caused by 
radiation, it has become important to develop agents 
that can prevent side effects. Free oxygen radicals that 
are exposed to ionizing radiation have a negative 
effect on antioxidant defense mechanisms in the cell. 
It reduces the activity of especially from the 
antioxidant enzymes present in the cell which are; 
superoxide dismutase (SOD), catalase (CAT), 
glutathione peroxidase (GSHPX)20,21. It is possible to 
prevent the damage by bringing radiotherapy to free 
radicals in normal cells using antioxidant agents. 
 
Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one), 
a free radical scavenger and neuroprotective agent 
used to treat dementia, mania and amyotrophic lateral 
sclerosis, has been reported to exhibit potential 
antioxidant effects22-24. Therapeutic effect is explained 
by its strong free radical scavenging property which 
has been proven in vivo and in vitro experimental 
studies25. Edaravone produces useful effects on 
oxidative stress markers including SOD, malon 
dialdehyde (MDA), GSHPX and CAT
22,23
. Edaravone 
has also been shown to have antiapoptotic, anti-
necrotic and anti-inflammatory effects26. It is 
expected that edaravone will have protective effect 
against radiation damage as it is a substance with free 
radical scavenging properties.  
 
Hence, in this study, we have made an attempt to 
evaluate biologically and histologically the possible 
protective effects of edaravone on lung and small 
intestine against radiation-induced early side effects 
of total body irradiation in single fraction.  
 
Materials and Methods 
 
Animals 
Thirty-two female Sprague Dawley rats (10-11 weeks, 
weight range 250 ± 25 g) were maintained under 
standard conditions. All experimental studies were 
conducted at Karadeniz Techniquel University 
Surgical Application and Research Center according 
to the guidelines for the ethical treatment of 
experimental animals. Local institutional approval for 
researchers was obtained before initiation of the 
study. The experimental protocol was approved by the 
Animal Care and Use Committee of Karadeniz 
Techniquel University (Protocol No: 2016/20).  
 
Experimental design  
The rats were divided randomly into four equal 
groups and there were 8 animals in each group. The 
study groups were designed as follows. Gr. I (Sham 
group): Rats were given intraperitoneal (i.p.) 1.0 mL 
of SF and 30 min after the administration of 90 mg/kg 
of ketamine i.p., general anesthesia was administered, 
follwed by 15 Gy of external ionizing radiation to the 
whole body under general anesthesia; Gr. II: Under 
general anesthesia the solution prepared by dissolving 
edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one; 
Sigma catalog no: M70800) in saline was 
administered i.p. at a dose of 500 mg/kg. After 30 min 
of EDA administration, the whole body was exposed 
to 15 Gy of external ionizing radiation; Gr. III: Under 
general anesthesia the EDA solution prepared at a 
dose of 50 mg/kg in saline was administered i.p. After 
30 min of EDA administration, 15 Gy of external 
ionizing radiation was administered to the whole 
body; Gr. IV (Control group): Without any 
intervention sacrificed at 72 h of the experiment. 
After 72 h27-29, the lungs and small intestines were 
removed and some of them are washed with cold 
isotonic saline solution and fixed in formalin for 
histopathological examination. The other part is 
reserved for biochemical measurements and stored  
at  ̶ 80ºC.  
 
Biochemical and Histopathologic assays 
Some of the tissues were separated with the 
intention to investigate tissue levels of GSHPX, SOD, 
CAT and MDA. GSHPX activity were measured by 
spectrophotometric assay kit (Cayman chemical 
company, USA) according to the manufacturer’s 
instructions. SOD activities in tissues were measured 
by Sun and Oberley method30. This method was based 
on reduction of nitroblue tetrazolium by xanthine-
xanthine oxidase system. Formazon formation was 
assessed spectrophotometrically at 560nm. CAT 
activity was determined by the method of Aebi31. This 
method is based on the principle that the absorbance 
at 240 nm decreases because of dismutation of H2O2. 
Other tissue samples were fixed for 48 h in 10% 
formol for histopathological evaluation. Tissue 
fragments were made transparent by passing through 
graded alcohol series. Paraffin blocks of the tissues 
were prepared and sections with thickness of 5 μM 
were taken from the blocks with a fully automated 
microtome. The sections were stained with 
hemetoxylene-eosin (H&E) after deparafinization, in 
order to evealuate inflammation, intraalveolar 




thickening, edema and capillary hyperemia in lungs32 
and inflammation, epithelial spillage and necrosis and 
degenerative changes in the intestines33. The 
evealuation has done that there was or not without 
grading. All samples were scored by pathologist 
blinded to experimental protocol and groups. 
 
Statistical analysis 
All values will be treated as mean ± Standard 
Deviation. Two-way ANOVA, Independent – 
Samples T-Test, Chi-Squere and Duncan multiple 
comparison tests was used to analyze the differences 
between the groups. (5% Type I error, 10% Type II 
error, and 6% SD admission, the minimum number of 
rats required to achieve an 18% difference between 
groups was 8 for each group). 
 
Results  
The study was designed to evaluate the early 
radioprotective effects of EDA (high and low doses) 
on lungs and small intestine damage induced by total 
body irridation to the rats as observed within 72 hours 
of administration.  
 
Biochemical results 
The protective effect of EDA showed statistically 
significant in MDA, SOD and GSHPX values of 
lungs compared to the control group (P <0.05). All 
the three groups, however, no statistically significant 
effect was observed in CAT results in irradiated  
lungs compared to the control (P >0.05).  
There was only statistically significant effect was 
observed in MDA results in irradiated small intestine 
compared to the control (P <0.05). There was no 
statistically significant effect observed in the other 
oxidative stress parameters of irradiated small 
intestine (P >0.05). However, when we compared the 
groups both lungs and small intestine in term of doses 
of EDA (Gr. II with Gr. III), there were statistically 
significant results in only GSHPX (P <0.05). 
 
Histopathological damage 
The lungs of the animals in the Gr.I, II and III were 
affected by irridation. The analysis of the irradiated 
lungs of rats with low and high dose EDA stained 
with H&E showed evident signs of inflammation, 
intraalveolar thickening and edema. The irridated 
lungs of rats with high dose EDA results were a little 
better than the low dose EDA results and the 
photomicrographs of histological slides of rat lungs 
were shown in Figs 1 A-D 2 and 3. However, no 
statistically significant effect was observed in 
capillary hyperemia results in irradiated lungs of rats 
compared to the control (P >0.05). They all showed 
 
 
Fig. 2 — Photomicrographs of histological slides of (A) any 
intraalveolar thickening from Gr. II; and (B) intraalveolar thickening 
(marked with arrows) of rat lungs from Gr. III (H&E 200X). 
 
 
Fig. 1 — Photomicrographs of histological slides of inflammation (marked with arrows) of rat lungs and small intestine. (A) Any 
inflammation from Gr. IV; (B) One positive of inflammation from Gr. II; (C) Two positive of inflammation from Gr. III; (D) Three positive 
of inflammation from Gr. I (sham group) ( H&E 400X); (E) Any inflammation from Gr. IV; (F) One positive of inflammation from Gr. II; 
(G) Two positive of inflammation from Gr. III; and (H) Three positive of inflammation from Gr. I (sham group) (H&E 100X). 




statistically significant findings compared to the 
control group (P <0.05) as showen in Table 1. 
The analysis of the irradiated small intestine of rats 
with low and high dose EDA stained with H&E 
showed evident signs of epithelial spillage and 
necrosis from Gr. I and III shown in Fig. 4. Also 
again high dose EDA results were beter than the low 
dose EDA results. Unfortunately no statistically 
significant effect was observed in inflammation 
results in irradiated small intestine of rats compared to 
the control (P >0.05). All groups had inflammation 
and there was any enough response from EDA to the 
small intetines of rats (Fig. 1 E-H). 
 
Discussion  
In this study, we evaluated the early (within 72 h of 
administration) radioprotective effects of EDA (high 
and low doses) on lungs and small intestine damage 
induced by total body irridation to the rats. The effect 
of EDA (low and high doses) therapy on the activities 
of antioxidant enzymes of GSHPX, SOD, CAT and 
MDA in the irridated rat lungs was investigated. Our 
results have shown that EDA reduced the increased 
activities of GSHPX, SOD and MDA on lungs except 
CAT especially with high doses. However, only MDA 
results have shown statistically significant differance 
in irradiated small intestine of rats. MDA is 
considered to be the index of lipid peroxidation  
and as expected, the first and early impact was seen  
in MDA results here in this study. The ionized 
radiation causes an increase in free radicals in the 
biological system. These radicals act on the DNA, 
proteins and membrane lipids of the cell to form cell 
damage. In addition, our histopathological results  
of lungs have shown statistically significant effect in 
lungs and small intestine except capillary hyperemia  
(in lungs) and inflammation (in small intestine). In our 
histopathological observation of lung, we also evaluated 
in terms of alveolar thickness, edema and capillary 
hyperemia besides inflammation, since inflammation 
could also occur in normal healthy animals. 
We observed that EDA reduced the inflammation, 
intraalveolar thickening and edema on lungs with high 
doses. Nevertheless we could not show the same 
effect on capillary hyperemia. Tajima et al.34 have 
shown that EDA alleviates the progression of lung 
injury and fibrosis. Also, Asai et al.35 demonstrated 
same effect of EDA on rabbit lungs by reflecting its 
ability to scavenge free radicals, which inhibits 
apoptosis and overexpression of transforming growth 
factor (TGF)-β. Our results have also shown 
statistically significant average on epithelial spillage 
and necrosis of small intestine with high doses of 
EDA between all experimental groups. On the other 
hand, inflammation of small intestine results have not 
shown any ststistically significant average between 
the groups.  
EDA clears various free radicals, and the irridation 
produces hydroxyl, peroxyl and superoxide radicals. 
Free radicals are removed by antioxidant enzymes in 
living cells and antioxidant defences SOD, GPX, 
 
 
Fig. 3 — Photomicrographs of histological slides of (A) any 
edema from Gr. II; and (B) edema (marked with arrow) of rat 
lungs from Gr. III ( H&E 400X). 
Table 1 — Histopathological results of lungs and small intestine 









Epithelial spillage and 
necrosis (n=8) 
Yes No Yes No Yes No Yes No Yes No Yes No 
I (n=8) 8 0 8 0 8 0 8 0 8 0 7 1 
II (n=8) 5 3 3 5 4 4 8 0 3 5 3 5 
III (n=8) 6 2 1 7 6 2 8 0 7 1 4 4 
IV (n=8) 1 7 2 6 2 6 7 1 2 6 0 7 




Fig. 4 — Photomicrographs of histological slides of epithelial 
spillage and necrosis (marked with arrows) of rat small intestines 
from (A) Gr. I, and (B) Gr. III (H&E 200X).  




CAT and glutathione. Many studies have shown that 
protective effect of EDA was associated with the 
increased SOD activitiy and CAT36. EDA applies a 
protective effect in animal models of myocardial, 
lung, intestinal, liver, bladder, testis, pancreatic and 
renal injuries26,37. EDA has also anti-apoptotic, anti-
necrotic and anti-cytokine effects in many different 
diseases and reduces the relase of adhesion molecules 
and markers of tumorigenesis37. Hassan et al.38 
suggested that EDA showed a potential protective 
effect in ISO (Isoproterenol)-induced myocardical 
infarction. Yoshizaki et al.39 have observed the 
benefical effects of EDA on fibrosis and eveluated for 
a potential use as an antifibrotic agent in systemic 
sclerosis. Ito et al.40 have found a protective effect  
of EDA againist lung injury induced intestine 
ischemia-reperfusion injury.  
 
Conclusion 
The pediatric cancer patients who have a longer life 
expectancy are as important as their recovery from 
their normal life. We found the protective effect of 
EDA showed statistically significant in MDA, SOD 
and GSHPX values of lungs except CAT and 
statistically significant effect was observed in MDA 
in small intestine of rats. Also we showed 
improvement in histopathological changings against 
radiation-induced in both the lung and the small 
intestines of rats. Finally edaravone is an effective 
drug for multiple organs and we expected to be able 
to reduce the side effects of radiation damage.  
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